GlobeNewswire by notified

Teledyne DALSA announces its new line of high-performance X-ray detectors at RSNA 2022

Share

New Axios IGZO-based X-ray detectors deliver an unrivaled balance of performance and value

WATERLOO, Ontario, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Teledyne DALSA is pleased to announce its presence at the RSNA 2022 Technical Exhibition with a new offering of X-Ray detectors based on Indium Gallium Zinc Oxide (IGZO) in addition to their premium line of CMOS-based detectors. The show takes place November 27 - December 1, Chicago, IL. Teledyne will exhibit its full line of detectors in booth #3709.

Teledyne will introduce its breakthrough line of X-ray detectors that narrows the gap between amorphous silicon and CMOS-based detectors at RSNA 2022. The new Axios flat panel detector series, designed and manufactured entirely by Teledyne, are based on an innovative IGZO technology, proprietary new image chain and use the highest performance components. The Axios product line is engineered to deliver an unprecedented balance of performance and value, while addressing the needs of the most demanding real-time applications for diagnostic and interventional imaging like orthopedics, vascular cardiology and surgery. The high image quality performance of the Axios detectors will enable better diagnosis of medical anomalies and better procedure outcomes, resulting in reduced treatment costs.

“Axios detectors exceed industry benchmarks in current TFT detector technologies by providing artifact-free images at higher speeds and higher DQE at low dose operation with lower lag and an increased signal-to-noise ratio,” said Mila Heeman, Marketing Manager for Teledyne DALSA’s X-Ray Solutions business unit. “The Axios detectors produce high performance 2D and 3D imaging at a considerably lower cost than the premium CMOS technology detectors. We are happy to offer more affordable, high-performance X-ray imaging bearing the Teledyne stamp of excellence in product quality and customer support.”

On display will be also the Teledyne’s Xineos CMOS X-Ray detector series – a superior performance family of detectors that deliver unsurpassed low dose and lag-free image quality, combined with easy integration and long reliable lifetime. These detectors provide the best digital imaging solution for challenging surgical situations — where all other technologies stop working, Teledyne’s CMOS goes the extra mile. Teledyne has a full portfolio of CMOS detectors in a wide range of detector sizes and resolutions for demanding x-ray imaging applications such as surgery, 2D and 3D mammography, extra oral dental, CBCT and others.

About Teledyne DALSA’s Healthcare Products and Services
Teledyne DALSA provides state-of-the-art image sensing, capture and processing solutions to medical, dental and scientific equipment manufacturers. Building on more than 30 years of proven capability and innovation, our team of imaging specialists delivers leading-edge product design. Our manufacturing processes are tailored to comply with the stringent quality, reliability, and traceability requirements of the medical and scientific X-ray community. For more information, visit http://teledynedalsa.com/imaging/markets/medical/

Media Contact:
Geralyn Miller
geralyn.miller@teledyne.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe50b5a8-c2fb-4a26-9188-a39f0ca35b74

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20228.12.2022 22:30:00 CET | Press release

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights11/30/2022 94,137,145 Total gross of voting rights: 94,137,145 Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.12.2022 22:00:00 CET | Press release

Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles o

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such8.12.2022 21:40:00 CET | Press release

COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associateda)NamePaul Chaplin2.Reason for the notificationa)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument Identification codeWarrants DK0015

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer8.12.2022 21:40:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnPaul Chaplin2.Årsag til indberetningena)Stilling/titelAdministrerende direktør i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen IdentifikationskodeTegningsoption

Bavarian Nordic iværksætter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere8.12.2022 21:35:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at udstede tegningsoptioner til koncernledelsen og udvalgte medarbejdere i Bavarian Nordic koncernen. Som et nyt initiativ vil erhvervelsen (vesting) af tegningsoptioner for medlemmer af koncernledelsen være baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er). Beslutningen er truffet i henhold til generalforsamlingens bemyndigelser til bestyrelsen, jf. vedtægternes § 5b og 5c, og i overensstemmelse med selskabets vederlagspolitik. Der tildeles i alt 248.787 tegningsoptioner til medlemmer af koncernledelsen til en udnyttelseskurs på DKK 224,70 pr. aktie, svarende til markedskursen for Bavarian Nordics aktie på tildelingstidspunktet. Erhvervelse af tegningsoptionerne er betinget af forudgående opfyldelse af KPI’er, som fastsættes af bestyrelsen. Der tildeles i alt 683.264 tegningsoptioner til udvalgte medarbejdere i Bavarian Nordic koncernen til